HAVCR2 and neoplasm: In summary, while cetuximab can elicit ADCC and ICD, resistance development is associated with increased M2 macrophages, PD-L1 upregulation (likely epigenetic), elevated PD-1/TIM-3 expression on lymphocytes, and increased Treg infiltration, ultimately compromising its anti-tumor efficacy.